16
Feb
2021

Genentech’s New AMD Contender, Takeda’s Win Against CMV, and the IPOs Continue

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

J&J Buys Ollin, Isomorphic’s Record Haul, & Who Wants to Lead FDA
RevMed’s Rollout, Yosemite Invests in Cancer & Servier’s Phase III Whiff
Anthropic Makes Noise, Silence Gets Bought, & GSK Gets HepB OK
BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro